source
- Novo Nordisk may secure more favorable terms under Medicare’s Bridge obesity drug programNovo Nordisk and Eli Lilly have been profiting from a Medicare pilot that caps obesity drug prices for seniors at $245 a month. Recent analysis suggests Novo could negotiate an even better arrangem…
- Novo Nordisk cuts 13,000 jobs to redirect funds toward R&DNovo Nordisk announced further workforce reductions, bringing total departures to about 13,000 over the past year. CEO Maziar Mike Doustdar said the cuts are intended to free up capital for resear…